Pranlukast, a novel binding ligand of human Raf1 kinase inhibitory protein
Objectives To study the binding of pranlukast to hRKIP and its regulatory role in the Raf1/MEK/ERK signal pathway. Results NMR and fluorescence experiments demonstrated hRKIP could bind pranlukast with a binding constant of 1016 $ mM^{−1} $. Residues (Y81, S109 and Y181) on the conserved ligand-binding pocket of hRKIP played a crucial role in binding pranlukast, and their mutations reduced the binding affinity more than 85 %. Furthermore, 25 μM pranlukast could up-regulate the ERK phosphorylation by about 17 %. Conclusion Pranlukast may be used as a potential drug precursor for treating hRKIP involved diseases..
Medienart: |
E-Artikel |
---|
Erscheinungsjahr: |
2016 |
---|---|
Erschienen: |
2016 |
Enthalten in: |
Zur Gesamtaufnahme - volume:38 |
---|---|
Enthalten in: |
Biotechnology letters - 38(2016), 8 vom: 05. Mai, Seite 1375-1380 |
Sprache: |
Englisch |
---|
Beteiligte Personen: |
Sun, Tao [VerfasserIn] |
---|
Links: |
Volltext [lizenzpflichtig] |
---|
BKL: | |
---|---|
Themen: |
ERK phosphorylation level |
Anmerkungen: |
© Springer Science+Business Media Dordrecht 2016 |
---|
doi: |
10.1007/s10529-016-2117-0 |
---|
funding: |
|
---|---|
Förderinstitution / Projekttitel: |
|
PPN (Katalog-ID): |
OLC2111681717 |
---|
LEADER | 01000naa a22002652 4500 | ||
---|---|---|---|
001 | OLC2111681717 | ||
003 | DE-627 | ||
005 | 20230503000339.0 | ||
007 | cr uuu---uuuuu | ||
008 | 230503s2016 xx |||||o 00| ||eng c | ||
024 | 7 | |a 10.1007/s10529-016-2117-0 |2 doi | |
035 | |a (DE-627)OLC2111681717 | ||
035 | |a (DE-He213)s10529-016-2117-0-e | ||
040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
041 | |a eng | ||
082 | 0 | 4 | |a 660 |q VZ |
084 | |a 42.30$jMikrobiologie |2 bkl | ||
084 | |a 58.30$jBiotechnologie |2 bkl | ||
100 | 1 | |a Sun, Tao |e verfasserin |4 aut | |
245 | 1 | 0 | |a Pranlukast, a novel binding ligand of human Raf1 kinase inhibitory protein |
264 | 1 | |c 2016 | |
336 | |a Text |b txt |2 rdacontent | ||
337 | |a Computermedien |b c |2 rdamedia | ||
338 | |a Online-Ressource |b cr |2 rdacarrier | ||
500 | |a © Springer Science+Business Media Dordrecht 2016 | ||
520 | |a Objectives To study the binding of pranlukast to hRKIP and its regulatory role in the Raf1/MEK/ERK signal pathway. Results NMR and fluorescence experiments demonstrated hRKIP could bind pranlukast with a binding constant of 1016 $ mM^{−1} $. Residues (Y81, S109 and Y181) on the conserved ligand-binding pocket of hRKIP played a crucial role in binding pranlukast, and their mutations reduced the binding affinity more than 85 %. Furthermore, 25 μM pranlukast could up-regulate the ERK phosphorylation by about 17 %. Conclusion Pranlukast may be used as a potential drug precursor for treating hRKIP involved diseases. | ||
650 | 4 | |a ERK phosphorylation level | |
650 | 4 | |a Fluorescence | |
650 | 4 | |a hRKIP | |
650 | 4 | |a Ligand binding pocket | |
650 | 4 | |a Pranlukast | |
650 | 4 | |a Phosphatidylethanolamine binding protein | |
650 | 4 | |a Protein binding | |
700 | 1 | |a Wu, Zhihua |4 aut | |
700 | 1 | |a Luo, Mengyao |4 aut | |
700 | 1 | |a Lin, Donghai |4 aut | |
700 | 1 | |a Guo, Chenyun |4 aut | |
773 | 0 | 8 | |i Enthalten in |t Biotechnology letters |d Springer Netherlands, 1979 |g 38(2016), 8 vom: 05. Mai, Seite 1375-1380 |h Online-Ressource |w (DE-627)312808356 |w (DE-600)2012203-2 |w (DE-576)107586002 |x 1573-6776 |7 nnns |
773 | 1 | 8 | |g volume:38 |g year:2016 |g number:8 |g day:05 |g month:05 |g pages:1375-1380 |
856 | 4 | 0 | |u https://dx.doi.org/10.1007/s10529-016-2117-0 |z lizenzpflichtig |3 Volltext |
912 | |a GBV_USEFLAG_A | ||
912 | |a SYSFLAG_A | ||
912 | |a GBV_OLC | ||
912 | |a GBV_ILN_11 | ||
912 | |a GBV_ILN_20 | ||
912 | |a GBV_ILN_22 | ||
912 | |a GBV_ILN_23 | ||
912 | |a GBV_ILN_31 | ||
912 | |a GBV_ILN_32 | ||
912 | |a GBV_ILN_39 | ||
912 | |a GBV_ILN_40 | ||
912 | |a GBV_ILN_60 | ||
912 | |a GBV_ILN_62 | ||
912 | |a GBV_ILN_63 | ||
912 | |a GBV_ILN_65 | ||
912 | |a GBV_ILN_69 | ||
912 | |a GBV_ILN_70 | ||
912 | |a GBV_ILN_73 | ||
912 | |a GBV_ILN_74 | ||
912 | |a GBV_ILN_90 | ||
912 | |a GBV_ILN_95 | ||
912 | |a GBV_ILN_100 | ||
912 | |a GBV_ILN_105 | ||
912 | |a GBV_ILN_110 | ||
912 | |a GBV_ILN_120 | ||
912 | |a GBV_ILN_138 | ||
912 | |a GBV_ILN_150 | ||
912 | |a GBV_ILN_151 | ||
912 | |a GBV_ILN_152 | ||
912 | |a GBV_ILN_161 | ||
912 | |a GBV_ILN_170 | ||
912 | |a GBV_ILN_187 | ||
912 | |a GBV_ILN_213 | ||
912 | |a GBV_ILN_224 | ||
912 | |a GBV_ILN_230 | ||
912 | |a GBV_ILN_285 | ||
912 | |a GBV_ILN_293 | ||
912 | |a GBV_ILN_370 | ||
912 | |a GBV_ILN_602 | ||
912 | |a GBV_ILN_636 | ||
912 | |a GBV_ILN_702 | ||
912 | |a GBV_ILN_2001 | ||
912 | |a GBV_ILN_2003 | ||
912 | |a GBV_ILN_2004 | ||
912 | |a GBV_ILN_2005 | ||
912 | |a GBV_ILN_2006 | ||
912 | |a GBV_ILN_2007 | ||
912 | |a GBV_ILN_2008 | ||
912 | |a GBV_ILN_2009 | ||
912 | |a GBV_ILN_2010 | ||
912 | |a GBV_ILN_2011 | ||
912 | |a GBV_ILN_2014 | ||
912 | |a GBV_ILN_2015 | ||
912 | |a GBV_ILN_2020 | ||
912 | |a GBV_ILN_2021 | ||
912 | |a GBV_ILN_2025 | ||
912 | |a GBV_ILN_2026 | ||
912 | |a GBV_ILN_2027 | ||
912 | |a GBV_ILN_2031 | ||
912 | |a GBV_ILN_2034 | ||
912 | |a GBV_ILN_2037 | ||
912 | |a GBV_ILN_2038 | ||
912 | |a GBV_ILN_2039 | ||
912 | |a GBV_ILN_2044 | ||
912 | |a GBV_ILN_2048 | ||
912 | |a GBV_ILN_2049 | ||
912 | |a GBV_ILN_2055 | ||
912 | |a GBV_ILN_2057 | ||
912 | |a GBV_ILN_2059 | ||
912 | |a GBV_ILN_2061 | ||
912 | |a GBV_ILN_2064 | ||
912 | |a GBV_ILN_2065 | ||
912 | |a GBV_ILN_2068 | ||
912 | |a GBV_ILN_2070 | ||
912 | |a GBV_ILN_2086 | ||
912 | |a GBV_ILN_2088 | ||
912 | |a GBV_ILN_2093 | ||
912 | |a GBV_ILN_2106 | ||
912 | |a GBV_ILN_2107 | ||
912 | |a GBV_ILN_2108 | ||
912 | |a GBV_ILN_2110 | ||
912 | |a GBV_ILN_2111 | ||
912 | |a GBV_ILN_2112 | ||
912 | |a GBV_ILN_2113 | ||
912 | |a GBV_ILN_2116 | ||
912 | |a GBV_ILN_2118 | ||
912 | |a GBV_ILN_2119 | ||
912 | |a GBV_ILN_2122 | ||
912 | |a GBV_ILN_2129 | ||
912 | |a GBV_ILN_2132 | ||
912 | |a GBV_ILN_2143 | ||
912 | |a GBV_ILN_2144 | ||
912 | |a GBV_ILN_2147 | ||
912 | |a GBV_ILN_2148 | ||
912 | |a GBV_ILN_2152 | ||
912 | |a GBV_ILN_2153 | ||
912 | |a GBV_ILN_2188 | ||
912 | |a GBV_ILN_2190 | ||
912 | |a GBV_ILN_2232 | ||
912 | |a GBV_ILN_2336 | ||
912 | |a GBV_ILN_2446 | ||
912 | |a GBV_ILN_2470 | ||
912 | |a GBV_ILN_2474 | ||
912 | |a GBV_ILN_2507 | ||
912 | |a GBV_ILN_2522 | ||
912 | |a GBV_ILN_2548 | ||
912 | |a GBV_ILN_4012 | ||
912 | |a GBV_ILN_4035 | ||
912 | |a GBV_ILN_4037 | ||
912 | |a GBV_ILN_4046 | ||
912 | |a GBV_ILN_4112 | ||
912 | |a GBV_ILN_4125 | ||
912 | |a GBV_ILN_4126 | ||
912 | |a GBV_ILN_4242 | ||
912 | |a GBV_ILN_4246 | ||
912 | |a GBV_ILN_4249 | ||
912 | |a GBV_ILN_4251 | ||
912 | |a GBV_ILN_4305 | ||
912 | |a GBV_ILN_4306 | ||
912 | |a GBV_ILN_4307 | ||
912 | |a GBV_ILN_4313 | ||
912 | |a GBV_ILN_4322 | ||
912 | |a GBV_ILN_4323 | ||
912 | |a GBV_ILN_4324 | ||
912 | |a GBV_ILN_4325 | ||
912 | |a GBV_ILN_4326 | ||
912 | |a GBV_ILN_4333 | ||
912 | |a GBV_ILN_4334 | ||
912 | |a GBV_ILN_4335 | ||
912 | |a GBV_ILN_4336 | ||
912 | |a GBV_ILN_4338 | ||
912 | |a GBV_ILN_4393 | ||
912 | |a GBV_ILN_4700 | ||
936 | b | k | |a 42.30$jMikrobiologie |q VZ |0 106419501 |0 (DE-625)106419501 |
936 | b | k | |a 58.30$jBiotechnologie |q VZ |0 106405365 |0 (DE-625)106405365 |
951 | |a AR | ||
952 | |d 38 |j 2016 |e 8 |b 05 |c 05 |h 1375-1380 |